Regulatory agencies require companies using microbial cell lines that produce products for human use to regularly complete biosafety testing to ensure that cell banks are free of phage contamination.

Bacteriophage (phage) is a virus that infects and replicates within bacteria1, basically bacterial predators. One hundred times smaller than a bacterium, phage are found wherever bacteria thrive and often exceed bacterial densities by an order of magnitude2. In fact, bacteriophage are the most abundant organisms in the biosphere and are thought to be the vectors of horizontal gene transfer that drives bacterial evolution3.

Phage have genetic material (DNA or RNA, single or double stranded) that is encapsulated by a protein coat and play a key role in bacterial biology by infecting bacteria and propagating by one of two methods4:

The lytic life cycle, when virulent phage infect a bacterium after attachment to a host cell receptor, inject nucleic acid, replicate and synthesize the capsid proteins. These de novo components are assembled to form a new viral particle. The lytic phages rapidly multiply causing cell lysis and on-going infection of the host bacteria.

In the lysogenic life cycle, phage either inserts its DNA into the host genome or remains as plasmid DNA in the host cell. In either case, the phage infection causes the host cell machinery to express phage genes by a process known as lysogenic conversion. Phage integrated into the genome of the bacterium are latent and called prophage until they revert to the lytic cycle.

The phage virus acts as a parasite and uses the metabolism of the bacterial cell to replicate and multiply. Phages also are also able to mobilize genetic material by transduction, or phage-mediated transfer of bacterial DNA between two bacterial cells.

Phage contamination of bacterial cultures is a common complication for the biotech and pharmaceutical industries. The presence of phage in cultures can bias results by interfering with bacterial identification and isolation. Phage are not susceptible to antibiotic treatments and therefore difficult to remove from infected cultures of bacteria5. Being ubiquitous and abundant, phage can become a serious problem for companies using microbial cell lines to produce recombinant products.

Regulatory agencies require companies using microbial cell lines that produce products for human use to regularly complete biosafety testing to ensure that cell banks are free of phage contamination. (US FDA (21 CFR Part 58 and 210/211) Both master cell banks (MCB), and end of production cell banks (EOP) must be tested regularly for phage contamination. The testing frequency varies between products and is regulated on a case by case basis by the applicable regulatory agency.

Phage testing includes both lytic and lysogenic testing with positive and negative controls in each type of testing. It is customary to contract a specialty lab to perform phage testing to avoid introducing positive phage controls into your manufacturing environment. GMP lot and/or batch release testing services for biologic drug substances or drug products are the core of Avance Biosciences’ business. We offer both lytic and lysogenic phage testing using several positive and negative controls for each type of test as well as a variety of additional biosafety testing services. Because we perform phage testing on a regular basis, our expertise in this area enables us to recognize any testing problems.

If you have a new bacterial cell line, a recently modified cell line, or are ready to bank your developed line, we offer mitomycin C induction followed by lysogenic testing to insure your cell bank is free of chromosome-integrated phage DNA. If detected, next generation sequencing is used for de novo construction of the contaminating phage sequence and blasted against the NCBI database to identify the contaminating phage. Additionally, we offer titer testing to determine the concentration of phage contamination, if any, in your bacterial cell bank.

Avance Biosciences offers comprehensive services for bacterial cell lines for all stages of production under cGMP/GLP regulatory compliance. Our team has more than two decades of experience and provides high quality cell bank characterization services. We can help you with fast and accurate testing results!

References

  1. Adams, M. H. (1959) Bacteriophages. 592. https://doi.org/10.1002/ange.19620740437
  2. Suttle, C.A. (2007) Marine viruses–major players in the global ecosystem. Nat Rev Microbiol 5(10):801-12. https://doi.org/10.1038/nrmicro1750
  3. Fortier, L.C. & Sekulovic, O. (2013) Importance of prophages to evolution and virulence of bacterial pathogens. Virulence 4(5):354-65. https://doi.org/10.4161/viru.24498
  4. Campbell, A. (2002) The future of bacteriophage biology. Nat Rev Genet 4(6):471-7. https://doi.org/10.1038/nrg1089
  5. Rakhuba, D.V., Kolomiets, E.I., Dey, E.S., Novik, G.I. (2010) Bacteriophage receptors, mechanisms of phage adsorption and penetration into host cell. Pol J Microbiol 59(3):145-55. http://www.pjm.microbiology.pl/archive/vol5932010145.pdf and Tzipilevich, E., Habusha, M., Ben-Yehuda, S. (2017) Acquisition of Phage Sensitivity by Bacteria through Exchange of Phage Receptors. Cell 168(1-2):186-199.e12. https://doi.org/10.1016/j.cell.2016.12.003

Have questions?

We are dedicated to timely, high-quality service from the start of your project to the finish. Send us a note or give us a call to find out what Avance can do for you.

SEND US A NOTE

Ready to get started?

Give us a little background on your needs and the goals of your project, and we’ll send a preliminary quote including: tasks, deliverables and a no-obligation cost estimate.

REQUEST A QUOTE

Our Customers Say…

From the preliminary conclusion of this work, we are already pleased to thank you for your customer-oriented approach and proactive communication in the course of this study. We are happy to see the profound difference in business mindset between your organization and our previous vendor…

Project Manager, Belgium

Thank you so much for successfully completing this important project for us on time. We are very satisfied with the final report and thank you for taking the extra effort to customize the report format. We will definitely use your lab for future projects.

Program Manager, California

It has been a pleasure working with you and your team. The project was carried out to the highest standard and delivered in a timely manner. I will definitely recommend Avance Biosciences’ services to colleagues and friends.

Senior Scientist, Singapore

When you partner with Avance Biosciences, we give you undivided attention, share our experience and knowledge, and respond to your needs in a timely manner. Contact our technical staff to discuss how we can support you in your project!

Partner

Dedication to Quality

Dedication To Quality

The Avance Biosciences team is committed to strict adherence to cGMP and GLP regulations enacted by the US, European, Japanese, and other international regulatory agencies.

LEARN MORE

Extensive Experience

Open Communication

Our team has extensive knowledge and experience working with scientists, QA/QC professionals, and project managers from over 100 pharmaceutical and biotechnology companies and organizations throughout the world.

LEARN MORE

Open Communication

Open Communication

Transparency and integrity are two of our core values. Our well-trained, friendly, and professional study directors and project managers strive to complete your projects on-time with open communication channels and to your specifications.

LEARN MORE

Cutting Edge Science

Open Communication

Avance Biosciences’ cGMP/GLP compliant genomic and microbial assays make use of the advanced technologies including real-time PCR, ddPCR, Sanger sequencing, next-gen sequencing, Southern blot, and more.

LEARN MORE